Related Experiment Video
Updated: Feb 23, 2026
10:54
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
Published on: November 21, 2025
580
Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study
Qijing Bo1, Feng Li1, Xianbin Li1
1Beijing Key Laboratory of Mental Disorders, Department of Psychiatry, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China; Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Ministry of Science and Technology, Beijing 100088, China.
Psychiatry Research
|September 4, 2017
Summary
One-year risperidone maintenance treatment improved remission rates in schizophrenia patients. Shorter illness duration and lower PANSS scores predicted better remission, potentially delaying relapse.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Schizophrenia treatment requires effective strategies to achieve and maintain remission.
- Risperidone is a widely used antipsychotic for schizophrenia management.
- Understanding factors influencing remission is crucial for optimizing patient outcomes.
Purpose of the Study:
- To investigate the impact of different risperidone dose-reduction strategies on remission rates in schizophrenia patients over one year.
- To identify predictors of remission and relapse in this patient population.
Main Methods:
- A one-year randomized controlled trial involving 374 clinically stabilized schizophrenia patients.
- Patients were assigned to 4-week, 26-week, or no-dose-reduction groups.
- Symptomatic remission was assessed monthly using the Positive and Negative Syndrome Scale (PANNS) and defined by established criteria.
Main Results:
- Remission rates increased significantly over the one-year study period across all groups.
- Longer duration of illness and shorter risperidone treatment length negatively impacted remission.
- Patients achieving remission at baseline had a significantly longer time to relapse.
Conclusions:
- One-year maintenance treatment with risperidone can enhance remission rates in schizophrenia.
- Shorter illness duration, longer risperidone treatment, and lower baseline PANSS scores are favorable predictors of remission.
- Achieving symptomatic remission may serve as a protective factor against relapse in schizophrenia.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
636
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
636
01:28Psychosis and Antipsychotic Drugs: Overview
1.0K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.0K
01:28Drug Therapy
320
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
320
01:29Psychological and Sociocultural Causes of Schizophrenia
697
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
697
01:21Antipsychotic Drugs: Typical and Atypical Agents
1.0K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.0K
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
956
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
956